Alessio Alogna, one of the founders of NanoPhoria, presented our inhalation-based approach to treat HFrEF in a large animal model at the American Heart Association’s annual Scientific Sessions event, which was held this year in Chicago (AHA 2022).
Read more: Program Planner (abstractsonline.com)
NanoPhoria has been granted an exclusive patent licence for a drug delivery platform based on inorganic nanoparticles. This acquisition will aid in the launch new products capable of optimizing the results of therapies and reducing side effects for patients.
Read more: Trasferimento tecnologico, Inail e CNR insieme per l’innovazione nella cura delle patologie cardiache – INAIL
NanoPhoria is on LinkedIn.
Read more: NanoPhoria: Informazioni | LinkedIn
NanoPhoria receives a 3.5M€ seed grant from Sofinnova Partners a leading European life sciences venture capital firm based in Paris, London and Milan.
Read more: Sofinnova Partners Announces New Investment In Nanophoria, Developer Of An Innovative Non-viral Drug Delivery Platform — Sofinnova Partners.
Trasferimento tecnologico: NanoPhoria, spin-off Cnr specializzato nella cura delle patologie cardiache, riceve un investimento seed di 3,5 milioni di euro da parte di Sofinnova Partners | Consiglio Nazionale delle Ricerche